Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
In a swift regulatory reversal, Hims & Hers Health Inc. (HIMS) has decided to stop selling a copycat version of Novo Nordisk's (NVO) Wegovy weight loss pill, just two days after launching the product. This decision triggered a nearly 16% drop in HIMS shares during after-hours trading. The move stems from mounting pressure from regulators, including a new U.S. Food and Drug Administration (FDA) warning on copycat weight loss drugs, and direct warnings from Novo Nordisk that the copy was illegal.
The Immediate Fallout: Hims Pulls the Plug on Wegovy Copycat
Hims & Hers announced the halt following "constructive conversations with stakeholders," as stated in a post on X. The company faced dual pressures: Novo Nordisk threatened legal action, and the Department of Health and Human Services referred Hims to the Department of Justice for potential federal law violations. Neither Novo nor the FDA provided immediate additional comments.
This incident highlights the precarious position of telehealth companies venturing into compounded versions of blockbuster GLP-1 receptor agonists like Wegovy (semaglutide). Wegovy, approved for chronic weight management, has driven massive demand in the obesity treatment market, but supply constraints previously opened doors for alternatives.
Background on Compounded GLP-1 Drugs and Wegovy
GLP-1 medications, such as Novo Nordisk's Wegovy and Ozempic (also semaglutide) or Eli Lilly's (LLY) Zepbound (tirzepatide), mimic hormones that regulate blood sugar and appetite. They promote significant weight loss—often 15-20% of body weight in clinical trials—making them a cornerstone of metabolic health therapy.
For years, telehealth firms like Hims & Hers have relied on compounding pharmacies to produce lower-cost versions of these drugs during FDA-declared shortages. Compounding involves customizing medications, which was permissible under Section 503A of the Federal Food, Drug, and Cosmetic Act when branded supplies were insufficient. This practice exploded as patient demand surged post-2021, with compounded semaglutide filling gaps.
However, as shortages have eased—Novo ramped up production, resolving the Wegovy shortage by late 2023—regulators have signaled a crackdown. The FDA's recent warning explicitly targets unauthorized compounded weight loss drugs, emphasizing safety risks like inconsistent dosing and contamination not present in FDA-approved products.
How Compounded Wegovy Copycats Differ from the Brand
- Branded Wegovy: FDA-approved, with precise dosing (starting at 0.25 mg weekly, titrating to 2.4 mg), rigorous quality control, and established cardiovascular safety data.
- Compounded Versions: Often cheaper ($200-400/month vs. $1,300+ for branded), but lack standardization, potentially leading to variable efficacy or adverse effects like nausea, gastrointestinal issues, or rare pancreatitis.
Patients using compounded GLP-1s should monitor for side effects closely; apps like Shotlee can help track symptoms, dosages, and progress during therapy.
Regulatory Shift: FDA and Big Pharma Push Back
Novo Nordisk and Eli Lilly have long argued the FDA hasn't done enough to curb knockoffs, which they claim undermine innovation and patient safety. This Hims case may signal a turning point: it's the first instance of a telehealth firm pulling a copycat product after a direct company complaint.
The FDA's stance aligns with broader efforts to enforce drug approval pathways. Post-shortage, compounding for "essentially a copy of a commercially available drug" violates regulations, per FDA guidance. The HHS-DOJ referral underscores potential criminal implications for non-compliance.
